Print Page  Close Window


SEC Filings

8-K
OREXIGEN THERAPEUTICS, INC. filed this Form 8-K on 05/03/2019
Entire Document
 


Case 18-10518-KG     Doc 1081     Filed 04/29/19     Page 4 of 11

 

In re: Orexigen Therapeutics, Inc.

   Case No. 18-10518 (KG)

Debtor

   Reporting Period: March 1, 2019 - March 31, 2019

 

MOR - 1

Consolidated Schedule of Cash Receipts and Disbursements (I)

For the Period: March 1, 2019 - March 31, 2019

(Unaudited)

 

$ USD ‘000s    March 1, 2019 - March 31, 2019      Cumulative
Since Filing
 

 

 

 Beginning Cash Balance (Book)

           $ 25,896      $ 21,372   

 Receipts

     

    Operating Receipts

            64,084   

    Miscellaneous Receipts

     46        71,526   

 

    

 

 

 

 Total Receipts

     46        135,611   

 Operating Disbursements

     

    Payroll & Benefits / Contractors

     (653)        (17,753)  

    Inventory

     (1)        (4,982)  

    Manufacturing and Logistics

            (205)  

    Gross to Net Disbursements

            (36,451)  

    Marketing / Commercial Operations

            (16,236)  

    Ordinary Course Professionals

     (8)        (1,179)  

    Rent / Facilities / Equipment

            (564)  

    Insurance

     (19)        (511)  

    IT / Utilities

            (376)  

    Regulatory and Compliance

            (675)  

    Other G&A

     (50)        (1,513)  

 

    

 

 

 

 Total Operating Disbursements

     (732)        (80,445)  

 Operating Cash Flow

     (686)        55,166   

 Reorganization Costs

     

    DIP Loan Interest and Fees

            (44,480)  

    US Trustee Fees

            (621)  

    Restructuring Professional Fees

 

    

 

(32)

 

 

 

    

 

(11,420)

 

 

 

 

    

 

 

 

 Total Reorganization Costs

     (32)        (56,521)  

 Total Disbursements

   $ (764)      $ (136,966)  

 

    

 

 

 

    Lender Professional Fees

     (21)        (2,460)  

 Net Cash Flow

   $ (739)      $ (3,815)  

 DIP Draw - Cash

            7,600   

 

    

 

 

 

 Ending Cash Balance (Book)

   $ 25,157      $ 25,157   
 Notes:      

 

    

(1) The Schedule of Cash Receipts and Disbursements is presented on a book basis.